Literature DB >> 24490020

Bosutinib in the treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia: an overview.

Ann Q Shen1, Nicole M Wilson2, Shannon L Gleason1, Hanna Jean Khoury3.   

Abstract

Bosutinib is an orally bioavailable SRC/ABL tyrosine kinase inhibitor with activity against all phases of resistant chronic myeloid leukemia that do not express the T315I or V299L ABL kinase domain mutations. Bosutinib has a unique toxicity profile that is manageable. This paper provides an overview of bosutinib, covering pharmacodynamics and pharmacokinetic properties, results of treatment in newly diagnosed and previously treated chronic myeloid leukemia patients, as well as common side effects.

Entities:  

Keywords:  bosutinib; chronic myeloid leukemia (CML); pharmacodynamic; pharmacokinetic; safety; tolerability; tyrosine kinase inhibitors (TKIs)

Year:  2014        PMID： 24490020      PMCID： PMC3891288          DOI： 10.1177/2040620713510481

Source DB:  PubMed          Journal:  Ther Adv Hematol        ISSN： 2040-6207


  7 in total

Review 1.  Chronic myeloid leukemia.

Authors:  C L Sawyers
Journal:  N Engl J Med       Date:  1999-04-29       Impact factor: 91.245

2.  In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.

Authors:  Miriam Puttini; Addolorata Maria Luce Coluccia; Frank Boschelli; Loredana Cleris; Edoardo Marchesi; Arianna Donella-Deana; Shaheen Ahmed; Sara Redaelli; Rocco Piazza; Vera Magistroni; Federica Andreoni; Leonardo Scapozza; Franca Formelli; Carlo Gambacorti-Passerini
Journal:  Cancer Res       Date:  2006-11-17       Impact factor: 12.701

3.  Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib.

Authors:  Jorge E Cortes; Hagop M Kantarjian; Tim H Brümmendorf; Dong-Wook Kim; Anna G Turkina; Zhi-Xiang Shen; Ricardo Pasquini; H Jean Khoury; Steven Arkin; Angela Volkert; Nadine Besson; Richat Abbas; Junyuan Wang; Eric Leip; Carlo Gambacorti-Passerini
Journal:  Blood       Date:  2011-08-24       Impact factor: 22.113

4.  SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.

Authors:  Jennifer M Golas; Kim Arndt; Carlo Etienne; Judy Lucas; Danielle Nardin; James Gibbons; Philip Frost; Fei Ye; Diane H Boschelli; Frank Boschelli
Journal:  Cancer Res       Date:  2003-01-15       Impact factor: 12.701

5.  Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial.

Authors:  Jorge E Cortes; Dong-Wook Kim; Hagop M Kantarjian; Tim H Brümmendorf; Irina Dyagil; Laimonas Griskevicius; Hemant Malhotra; Christine Powell; Karïn Gogat; Athena M Countouriotis; Carlo Gambacorti-Passerini
Journal:  J Clin Oncol       Date:  2012-09-04       Impact factor: 44.544

6.  Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.

Authors:  Heiko Konig; Tessa L Holyoake; Ravi Bhatia
Journal:  Blood       Date:  2007-12-04       Impact factor: 22.113

7.  Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure.

Authors:  H Jean Khoury; Jorge E Cortes; Hagop M Kantarjian; Carlo Gambacorti-Passerini; Michele Baccarani; Dong-Wook Kim; Andrey Zaritskey; Athena Countouriotis; Nadine Besson; Eric Leip; Virginia Kelly; Tim H Brümmendorf
Journal:  Blood       Date:  2012-02-27       Impact factor: 22.113
  7 in total
  4 in total

Review 1.  Clinical advances in the management of chronic myelogenous leukemia: focus on bosutinib and patient considerations.

Authors:  Kendra Sweet; Javier Pinilla-Ibarz; Ling Zhang
Journal:  Patient Prefer Adherence       Date:  2014-07-08       Impact factor: 2.711

Review 2.  The Role of MicroRNAs in Myeloproliferative Neoplasia.

Authors:  Shaban Alizadeh; Seyed Ghader Azizi; Masoud Soleimani; Yadollah Farshi; Zahra Kashani Khatib
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2016-07-01

3.  Bosutinib-Induced Stevens-Johnson Syndrome and Evidence of Tolerance to a Structurally Dissimilar Tyrosine Kinase Inhibitor.

Authors:  Karol Avila-Castano; Dan Morgenstern-Kaplan; Ismael Carrillo-Martin; Alexei Gonzalez-Estrada
Journal:  Cureus       Date:  2022-03-18

Review 4.  Bosutinib for Chronic Myeloid Leukemia.

Authors:  Massimo Breccia; Gianni Binotto
Journal:  Rare Cancers Ther       Date:  2015-08-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.